Physician profile
Michael E Killian
NPI 1851342026
$12,566.09
in general payments reported to CMS, 2019-2025
53 companies · $2,409 in 2025
The $2,409 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,915 · 2020: $631 · 2021: $635 · 2022: $1,900 · 2023: $2,201 · 2024: $1,874 · 2025: $2,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,475 · Education: $10.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,474.52 |
| Education | $10.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,489.96 | 2019-2025 | Biktarvy |
| Novo Nordisk INC | $1,306.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,092.09 | 2019-2025 | |
| Viiv Healthcare Company | $1,083.52 | 2019-2025 | Apretude, Rukobia, Cabenuva |
| Lilly USA, LLC | $733.45 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $727.12 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $581.85 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $580.20 | 2019-2025 | Trintellix |
| Pfizer INC. | $545.65 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.80 | 2019-2025 | Jardiance |
| Emd Serono, INC. | $310.65 | 2019-2025 | Serostim |
| Amgen INC. | $283.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $203.60 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Merck Sharp & Dohme LLC | $178.38 | 2022-2025 | Capvaxive, Gardasil 9, Pifeltro |
| Phathom Pharmaceuticals, INC. | $162.11 | 2024-2025 | Voquezna |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Killian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.